Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Viasat Drops 29%: Falling Knife or Moonshot Bargain?: https://www.marketbeat.com/logos/articles/med_20230717134826_viasat-drops-29-falling-knife-or-moonshot-bargain.jpg
Viasat Drops 29%: Falling Knife or Moonshot Bargain?

Last month, digital satellite telecommunications pioneer Viasat, Inc. (NASDAQ: VSAT) was on top of the world. The company had just wrapped up a $7.3 billion acquisition of U.K. rival Inmarsat to

Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. Sensationelle Studienergebnisse. 20% der Patienten vollständig geheilt. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Am: https://www.irw-press.at/prcom/images/messages/2023/71359/AC_VidacPharma_180723.001.png
Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. Sensationelle Studienergebnisse. 20% der Patienten vollständig geheilt. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Am

Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. 204% Biotech Aktientip nach 10.996% mit Pfizer

 

18.07.23 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Nvidia Invested $50 million into This AI Drug Discovery Biotech: https://www.marketbeat.com/logos/articles/med_20230716132259_chart-rxrx.jpg
Nvidia Invested $50 million into This AI Drug Discovery Biotech

Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader

3 Dividend Stocks That Still Make Sense in 2023: https://www.marketbeat.com/logos/articles/med_20230717061732_3-dividend-stocks-that-still-make-sense-in-2023.jpg
3 Dividend Stocks That Still Make Sense in 2023

It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. Dividend-paying stocks give investors a reward for simply holding on to the stock. That

Eilt: 20% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). : https://www.irw-press.at/prcom/images/messages/2023/71350/AC-170723.001.png
Eilt: Hautkrebs-Studie mit sensationellen Ergebnissen - Massives Kaufsignal. Neuer 204% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71337/AC-140723.001.png
3 Biotech Stocks to Buy for Long-Term Gains: https://www.marketbeat.com/logos/articles/med_20230712120806_3-biotech-stocks-to-buy-for-long-term-gains.jpg
3 Biotech Stocks to Buy for Long-Term Gains

Suppose you’re looking for a sector that will benefit from an end to the Federal Reserve’s interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with

Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen

 

12.07.23 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi: https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. (NASDAQ: BIIB) swooned 2.88% in heavy trading volume following news of full

Pfizer Just Invested $25 million In This Biotech: https://www.marketbeat.com/logos/articles/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg
Pfizer Just Invested $25 million In This Biotech

Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen

 

05.07.23 08:17

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies

Drugmaker GSK: Becoming a Healthier Value Stock: https://www.marketbeat.com/logos/articles/med_20230627104026_drugmaker-gsk-is-becoming-a-healthier-value-stock.jpg
Drugmaker GSK: Becoming a Healthier Value Stock

Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets: https://www.marketbeat.com/logos/articles/med_20230625124449_chart-petv.jpg
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?): https://www.marketbeat.com/logos/articles/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)

ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials: https://www.marketbeat.com/logos/articles/med_20230625130240_chart-imgn2.jpg
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver

T-Mobile Stock's Decline: Does Value Potential Exist?: https://www.marketbeat.com/logos/articles/med_20230621142449_t-mobile-stocks-decline-does-value-potential-exist.jpg
T-Mobile Stock's Decline: Does Value Potential Exist?

Investors rarely get to consider a blue-chip company like T-Mobile US (NASDAQ: TMUS) amid a decline of more than 17% during the past two months. As the underlying stock carries a beta of only

Bullish or Bearish? Vetting Animal Health Care Stocks: https://www.marketbeat.com/logos/articles/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg
Bullish or Bearish? Vetting Animal Health Care Stocks

Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed. 

As Fido and Fluffy were spoiled more